Associate Professor Stanko Skrtic
Soborg (Sweden)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease
Event: ESC Congress 2017
Topic: Drug therapy
Session: Best Posters in new targets in cardiovascular drug assessment
ESC 365 is supported by
